Co-formulation of the rF1V plague vaccine with depot-formulated cytokines enhances immunogenicity and efficacy to elicit protective responses against aerosol challenge in mice.

Autor:	Galloway DR; Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, United States., Li J; Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, United States., Nguyen NX; Department of Pathology, Division of Microbiology and Immunology, University of Utah, Salt Lake City, UT, United States., Falkenberg FW; CIRES, GmbH, Bochum, Germany.; CyTuVax BV, Maastricht, Netherlands., Henning L; Battelle Biomedical Research Center, Columbus, OH, United States., Krile R; Battelle Biomedical Research Center, Columbus, OH, United States., Chou YL; Battelle Biomedical Research Center, Columbus, OH, United States., Herron JN; Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, United States., Hale JS; Department of Pathology, Division of Microbiology and Immunology, University of Utah, Salt Lake City, UT, United States., Williamson ED; Chemical Biological Radiological Division, Defense Science and Technology Laboratory (DSTL), Porton Down, Salisbury, United Kingdom.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2024 Mar 28; Vol. 15, pp. 1277526. Date of Electronic Publication: 2024 Mar 28 (Print Publication: 2024).
DOI:	10.3389/fimmu.2024.1277526
Abstrakt:	This study evaluated a depot-formulated cytokine-based adjuvant to improve the efficacy of the recombinant F1V (rF1V) plague vaccine and examined the protective response following aerosol challenge in a murine model. The results of this study showed that co-formulation of the Alhydrogel-adsorbed rF1V plague fusion vaccine with the depot-formulated cytokines recombinant human interleukin 2 (rhuIL-2) and/or recombinant murine granulocyte macrophage colony-stimulating factor (rmGM-CSF) significantly enhances immunogenicity and significant protection at lower antigen doses against a lethal aerosol challenge. These results provide additional support for the co-application of the depot-formulated IL-2 and/or GM-CSF cytokines to enhance vaccine efficacy. Competing Interests: Author FF was employed by companies CIRES GmbH and CyTuVax BV. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 Galloway, Li, Nguyen, Falkenberg, Henning, Krile, Chou, Herron, Hale and Williamson.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu